Story perspectives

Biocon's Liraglutide Injection Gains FDA Approval for Weight Management

2/25/2026

Summary

Story summary

Biocon Limited received U.S. FDA approval on February 24, 2026, for Liraglutide Injection (gSaxenda®) for chronic weight management.
Drug-device combination complements a reduced-calorie diet and increased physical activity.
Approval validates Biocon Limited's ability to develop complex formulations and opens access to U.S. GLP-1 market worth $127 million.
CEO Siddharth Mittal highlighted Biocon Limited's commitment to affordable treatments and noted risks from past scrutiny of manufacturing facilities and Novo Nordisk's competition.

1 of 1

Story summary

Biocon Limited received U.S. FDA approval on February 24, 2026, for Liraglutide Injection (gSaxenda®) for chronic weight management.
Drug-device combination complements a reduced-calorie diet and increased physical activity.
Approval validates Biocon Limited's ability to develop complex formulations and opens access to U.S. GLP-1 market worth $127 million.
CEO Siddharth Mittal highlighted Biocon Limited's commitment to affordable treatments and noted risks from past scrutiny of manufacturing facilities and Novo Nordisk's competition.